Research Analysts Issue Forecasts for NAMS Q3 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Equities researchers at HC Wainwright issued their Q3 2026 earnings estimates for shares of NewAmsterdam Pharma in a research note issued to investors on Thursday, February 19th. HC Wainwright analyst L. Egana-Gorrono anticipates that the company will post earnings per share of ($0.59) for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday. Stifel Nicolaus increased their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Leerink Partners restated an “outperform” rating and set a $55.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group increased their price objective on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research report on Tuesday, December 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $47.00.

NewAmsterdam Pharma Trading Up 2.7%

NASDAQ NAMS opened at $35.58 on Friday. The firm’s fifty day simple moving average is $33.97 and its two-hundred day simple moving average is $32.54. The firm has a market capitalization of $4.03 billion, a P/E ratio of -20.57 and a beta of 0.06. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently modified their holdings of the stock. Jennison Associates LLC grew its stake in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after acquiring an additional 1,252,451 shares during the period. Atle Fund Management AB raised its position in NewAmsterdam Pharma by 23.2% during the third quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock worth $5,507,000 after acquiring an additional 36,402 shares during the period. Keybank National Association OH purchased a new position in NewAmsterdam Pharma during the third quarter valued at $455,000. Franklin Resources Inc. grew its position in shares of NewAmsterdam Pharma by 30.6% in the second quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock valued at $6,053,000 after purchasing an additional 78,300 shares during the period. Finally, Frazier Life Sciences Management L.P. grew its position in shares of NewAmsterdam Pharma by 3.0% in the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after purchasing an additional 490,656 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 32,612 shares of the business’s stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at $774,425.40. The trade was a 57.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $33.25, for a total transaction of $199,500.00. Following the completion of the sale, the insider directly owned 73,481 shares in the company, valued at approximately $2,443,243.25. The trade was a 7.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 298,647 shares of company stock valued at $10,236,050. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.